CVS
New money, same old pharmacy giant
CVS just picked up a new fan club member: Third View Private Wealth LLC opened a position of 34,895 shares, worth about $2.77 million. For a stock that’s spent plenty of time being treated like a sleepy health-care utility, a fresh institutional buy is a nice reminder that big money still sees value here.
The “actually, that’s pretty decent” part
This wasn’t just a random stake taken in a vacuum. CVS also posted a beat, with EPS of $1.09 versus the $1.00 Wall Street expected and revenue of $105.69 billion versus $103.67 billion. It then guided FY2026 EPS to $5.94–$6.14, which is basically management saying, “We’re not dead yet.”
Dividend candy, with a side of warning label
The company also declared a quarterly dividend of $0.665 a share, which works out to a 3.4% yield at recent prices. That’s the good news. The eyebrow-raising bit? The payout ratio is around 192.8%, which is a little like financing your pizza habit with a very optimistic credit card.
What investors should watch
Analysts are still leaning constructive, with a consensus “Moderate Buy” and an average price target of $94.95, above the recent stock price near $78.12. So the setup is basically: new institutional money in the door, earnings looking sturdier, but the dividend math still deserves a side-eye.
Big picture: CVS is getting a credibility boost, but the market will want proof that the turnaround can keep paying — literally and figuratively.